ArticleNaunyn-Schmiedeberg's archives of pharmacology2025
Piceatannol protects against cisplatin-induced ovarian toxicity in rats via modulation of PTEN/PI3 K/AKT axis.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Piceatannol Attenuates Benzo[Journal of agricultural and food chemistry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Premenopausal women diagnosed with cancer may suffer from ovarian toxicity, which affects their quality of life. Cisplatin (CIS) is an effective chemotherapeutic drug used for different types of tumors. However, CIS has been reported to cause ovarian toxicity. Aberration of the PI3K/AKT signaling has been implicated in CIS-induced ovarian toxic effects. Piceatannol (PIC) is a naturally occurring polyphenolic stilbene that has garnered significant research interest due to its known antioxidant, anti-inflammatory, and anti-apoptotic activities. The aim of this study was to investigate the potential protective role of PIC against CIS-induced ovarian toxicity in female rats. Thirty female rats were divided randomly into five groups, and treated for 17 days. (1) control, (2): PIC (10 mg/kg), (3): CIS (6 mg/kg), (4): low dose PIC (5 mg/kg) + CIS (6 mg/kg), and (5): high dose PIC (10 mg/kg) + CIS (6 mg/kg). Pretreatment with PIC significantly prevented the CIS-induced histopathological alterations, inhibited follicles loss, and inhibited the decrease in serum AMH. PIC exhibited antioxidant activity by significantly preventing MDA production and the depletion of GSH and antioxidant enzymes in ovarian tissues in a dose-dependent manner. PIC markedly decreased the immunostaining expression of iNOS, TNF-α, and NF-κB in ovarian tissues. Furthermore, PIC significantly attenuated immune-expression of PTEN and enhanced those of PI3K and phosphor-AKT in ovarian tissues of CIS-treated rats. Finally, PIC modulated mRNA expression of Bcl-2, BAX and CASP3 in favor of anti-apoptosis. PIC protects against CIS-induced ovarian toxicity by exerting antioxidant, anti-inflammatory, and anti-apoptotic effects, primarily through modulation of the PTEN/PI3K/p-AKT axis.
Indexed as
Identifiers
40512215What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.